![FDA's Generic Drug Program in 2020 Helped Ensure Availability of High-Quality, Affordable Drugs Amid COVID-19 | FDA FDA's Generic Drug Program in 2020 Helped Ensure Availability of High-Quality, Affordable Drugs Amid COVID-19 | FDA](https://www.fda.gov/files/styles/main_image_medium/public/Generic-Drug-Program-2020-FDA-Voices-1600x900.png?itok=FJvaeAZw)
FDA's Generic Drug Program in 2020 Helped Ensure Availability of High-Quality, Affordable Drugs Amid COVID-19 | FDA
![Safety, Efficacy, and Quality Remain Top Priorities as We Continue Our Work to Expand Access to Cost-Saving Generic Drugs for the American Public | FDA Safety, Efficacy, and Quality Remain Top Priorities as We Continue Our Work to Expand Access to Cost-Saving Generic Drugs for the American Public | FDA](https://www.fda.gov/files/generic-drugs-900x900.jpg)
Safety, Efficacy, and Quality Remain Top Priorities as We Continue Our Work to Expand Access to Cost-Saving Generic Drugs for the American Public | FDA
![Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study | Scientific Reports Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study | Scientific Reports](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41598-020-62318-y/MediaObjects/41598_2020_62318_Fig1_HTML.png)
Comparative effectiveness of branded vs. generic versions of antihypertensive, lipid-lowering and hypoglycemic substances: a population-wide cohort study | Scientific Reports
![Bye-bye, blockbuster? AstraZeneca's Faslodex gets U.S. generic on heels of record sales year | Fierce Pharma Bye-bye, blockbuster? AstraZeneca's Faslodex gets U.S. generic on heels of record sales year | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1559310272/AstraZeneca%20Faslodex%20package.jpg/AstraZeneca%20Faslodex%20package.jpg?VersionId=bTLCc3179_20TldkDpXTtNIFvcyasvUu)
Bye-bye, blockbuster? AstraZeneca's Faslodex gets U.S. generic on heels of record sales year | Fierce Pharma
![Reforms Are Needed To Rein In Health Spending, But Reference Pricing Isn't Worth The Risk | Health Affairs Reforms Are Needed To Rein In Health Spending, But Reference Pricing Isn't Worth The Risk | Health Affairs](https://www.healthaffairs.org/do/10.1377/forefront.20211004.561448/full/health-affairs-blog-referencepricing-pharmaceuticals-buelt.png)
Reforms Are Needed To Rein In Health Spending, But Reference Pricing Isn't Worth The Risk | Health Affairs
![A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways - Klein - 2021 - Annals of the New York Academy of Sciences - Wiley Online Library A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways - Klein - 2021 - Annals of the New York Academy of Sciences - Wiley Online Library](https://nyaspubs.onlinelibrary.wiley.com/cms/asset/9cd811b3-0014-4654-9b5c-7525ffeb9cc5/nyas14662-gra-0001-m.jpg)
A pragmatic regulatory approach for complex generics through the U.S. FDA 505(j) or 505(b)(2) approval pathways - Klein - 2021 - Annals of the New York Academy of Sciences - Wiley Online Library
![Value-Based Pricing of Prescription Drugs Benefits Patients and Promotes Innovation - Center for American Progress Value-Based Pricing of Prescription Drugs Benefits Patients and Promotes Innovation - Center for American Progress](https://www.americanprogress.org/wp-content/uploads/2021/09/ValueBasedDrugPricing.jpg?w=1040)